We are proud to announce the recent expansion of our portfolio of companies. We welcome two newcomers - Incephalo and NextImmune - to our family.…
Sina Kohlbrenner23.06.2021
Synendos is developing first-in-class inhibitors. These inhibitors modulate a newly identified drug target in the body’s endocannabinoid system which is a key neuromodulator system in…
Sina Kohlbrenner20.04.2021
We are very proud to announce that Synendos Therapeutics has raised a USD 21M series A co-led by Kurma Partners and Sunstone Life Science Ventures.…
Sina Kohlbrenner11.11.2020
Polyneuron Pharmaceuticals, a BaseLaunch portfolio company, has concluded the extension of its Series A financing round. With further investment of 14 million francs, the startup has…
Sina Kohlbrenner17.09.2020
This second closing of CHF 4.7M is led by BioMedPartners AG and Altos Ventures AG, who are joining the previous investors Redalpine Venture Partners AG,…
Sina Kohlbrenner19.08.2020
Dr. Iacone is a physician-scientist with more than 15 years of experience in the life science industry. Before Alentis he was Global Head of Rare…
Sina Kohlbrenner19.08.2020
Versameb also welcomes Dr. Klaas P. Zuideveld as Chief Development Officer. Prior to Versameb he was Vice President of Partnerships at Caris Life Sciences, and…
Sina Kohlbrenner19.08.2020
The orphan drug designation can only be granted for treatments on rare diseases to advance the developments of safe and effective therapies and the FDA…
Sina Kohlbrenner19.08.2020
PharmaBiome also welcomed two new board members with extensive biotech and entrepreneurial experience, all the way from founding to IPO. Dr. Thomas Meier joins PharmaBiome…
Sina Kohlbrenner19.08.2020
